# Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours

> **NCT01859351** · PHASE1 · TERMINATED · sponsor: **Heidelberg Pharma AG** · enrollment: 13 (actual)

## Conditions studied

- Advanced Solid Tumours

## Interventions

- **DRUG:** WX-037
- **DRUG:** WX-554

## Key facts

- **NCT ID:** NCT01859351
- **Lead sponsor:** Heidelberg Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-07
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Study terminated for business reasons
- **Last updated:** 2014-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01859351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01859351, "Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT01859351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*